• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of lipid measures and risk stratification among end-stage renal disease patients.

作者信息

Bowden Rodney G, Hebert Stuart, Wilson Ronald, Gentile Mindy, Lanning Beth A

机构信息

Department of Health, Human Performance, and Recreation, Baylor University, Waco, Texas 76798-7313, USA.

出版信息

J Nephrol. 2007 Mar-Apr;20(2):212-8.

PMID:17514626
Abstract

BACKGROUND

Abnormal lipid profiles are associated with end-stage renal disease (ESRD) which significantly contributes to an accelerated progression of coronary artery disease. The purpose of this study was to examine the relationships between cholesterol measures and differences in risk stratification when using National Cholesterol Education Program, Adult Treatment Panel, Third Report (ATP-III) guidelines, compared with cholesterol particle number and size in ESRD patients.

METHODS

Lipid profiles were conducted on 541 ESRD patients who were chronic hemodialysis patients. Lipid profiles were measured using gel electrophoresis and their particle size and concentration measured using nuclear magnetic resonance (NMR) spectroscopy. Correlations and risk stratification were compared between each lipid measure.

RESULTS

The findings suggest that low-density lipoprotein (LDL) size does not correlate well with LDL cholesterol and LDL particle number. The findings also suggest a "disconnect" between traditional lipid measures and cholesterol concentration and size when using ATP-III guidelines for risk stratification.

CONCLUSIONS

The cholesterol risk designation variances between risk stratification guidelines and the relationships established through Pearson correlations, as illustrated within this patient pool, reveal the complex differences between measures of coronary artery disease risk. These additional patients considered at-risk using NMR technology may help to identify more patients at need for intervention and treatment.

摘要

相似文献

1
Comparison of lipid measures and risk stratification among end-stage renal disease patients.
J Nephrol. 2007 Mar-Apr;20(2):212-8.
2
The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.使用别嘌醇降低尿酸水平对终末期肾病患者代谢综合征标志物的影响:一项初步研究。
Anadolu Kardiyol Derg. 2009 Oct;9(5):385-9.
3
Are the anticardiolipin antibodies a risk factor for coronary artery disease in chronic renal failure patients?抗心磷脂抗体是慢性肾衰竭患者冠状动脉疾病的危险因素吗?
Ren Fail. 2008;30(8):791-5. doi: 10.1080/08860220802249017.
4
Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.补充ω-3脂肪酸对终末期肾病患者血脂水平的影响。
J Ren Nutr. 2009 Jul;19(4):259-66. doi: 10.1053/j.jrn.2009.01.030.
5
Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.降低成人低密度脂蛋白胆固醇:一项基于社区的前瞻性实践倡议。
Am J Med. 2008 Jul;121(7):604-10. doi: 10.1016/j.amjmed.2008.02.031. Epub 2008 Jun 4.
6
Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.基于模型的模拟,以探讨遵循糖尿病和混合性血脂异常患者甘油三酯和低密度脂蛋白胆固醇控制实践指南的成本效益。
Clin Ther. 2009 Apr;31(4):862-79. doi: 10.1016/j.clinthera.2009.04.015.
7
Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients.脂质-死亡关联的反向流行病学研究:一项终末期肾病患者队列研究。
Nephron Clin Pract. 2011;119(3):c214-9. doi: 10.1159/000329509. Epub 2011 Aug 11.
8
Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.接受血液透析和腹膜透析患者的负电低密度脂蛋白及脂质异常
Nephron Clin Pract. 2008;108(4):c298-304. doi: 10.1159/000127982. Epub 2008 Apr 24.
9
Lipoperoxidation and hemodialysis.脂质过氧化与血液透析
Metabolism. 2008 Oct;57(10):1369-74. doi: 10.1016/j.metabol.2008.05.004.
10
Non-high-density lipoprotein cholesterol in secondary prevention of coronary artery disease: a unique risk factor or redundant information?非高密度脂蛋白胆固醇在冠状动脉疾病二级预防中的作用:一个独特的危险因素还是冗余信息?
J Cardiopulm Rehabil Prev. 2007 Nov-Dec;27(6):386-9. doi: 10.1097/01.HCR.0000300266.92516.6a.

引用本文的文献

1
The Effects of Lowering Uric Acid Levels Using Allopurinol on Components of Metabolic Syndrome.使用别嘌醇降低尿酸水平对代谢综合征各组分的影响
Cardiol Res. 2012 Apr;3(2):80-86. doi: 10.4021/cr168w. Epub 2012 Mar 20.
2
Lipoprotein subfractions and particle size in end-stage renal disease.终末期肾病中的脂蛋白亚组分与颗粒大小
Clin J Am Soc Nephrol. 2011 Dec;6(12):2738-9. doi: 10.2215/CJN.10281011.
3
LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.在终末期肾病患者中,与 LDL 胆固醇和风险分类相比,LDL 颗粒大小和数量。
J Nephrol. 2011 Nov-Dec;24(6):771-7. doi: 10.5301/JN.2011.6376.